Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access GSM
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
9M 2017 Results presentation
Operating income, growth figures, profitability and how our products have behaved.
Wed, 08/11/2017 - 08:32
0 min
Result_presentacion.jpg
Download related document
Select rating
Give 9M 2017 Results presentation 1/5
Give 9M 2017 Results presentation 2/5
Give 9M 2017 Results presentation 3/5
Give 9M 2017 Results presentation 4/5
Give 9M 2017 Results presentation 5/5
No votes yet
Related
Final Decision to award aid of 36.3 million euros for ROVI’s LAISOLID project...
Madrid, 10 July 2025. Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 9 July 2025, the Technological...
4 min
10/07/2025
ROVI held its 2025 General Shareholders’ Meeting
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
ROVI to receive 36.3 million euros for research into prolonged-release drugs...
Madrid, 8 May 2025.- Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 7 May 2025, the Technological Development...
4 min
08/05/2025
See More
Email
Facebook
Twitter
LinkedIn
Result_presentacion.jpg